Ebola virus - Mayinga, Zaire, 1976

Summary

Alias: Ebola virus strain Zaire Mayinga, Ebola virus (strain Zaire Mayinga), Zaire ebolavirus - Mayinga (Zaire, 1976), Zaire ebolavirus Mayinga strain

Top Publications

  1. ncbi Ebola virus matrix protein VP40 interaction with human cellular factors Tsg101 and Nedd4
    Joanna Timmins
    European Molecular Biology Laboratory, 6 rue Jules Horowitz, 38042 Grenoble, France
    J Mol Biol 326:493-502. 2003
  2. ncbi Ebola virus glycoprotein GP is not cytotoxic when expressed constitutively at a moderate level
    Nathalie Alazard-Dany
    Filovirus Laboratory, Claude Bernard University Lyon 1, INSERM U758, IFR 128 Biosciences Lyon Gerland, France
    J Gen Virol 87:1247-57. 2006
  3. pmc Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles
    Jillian M Licata
    Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, 3800 Spruce St, Philadelphia, PA 19104 6049, USA
    J Virol 78:7344-51. 2004
  4. pmc Ebola virus can be effectively neutralized by antibody produced in natural human infection
    T Maruyama
    Departments of Immunology and Molecular Biology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 73:6024-30. 1999
  5. pmc Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP
    Takeshi Noda
    Laboratory of Microbiology, Department of Disease Control, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo 060 0818, Japan
    J Virol 76:4855-65. 2002
  6. pmc Ebola virus-like particles protect from lethal Ebola virus infection
    Kelly L Warfield
    US Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA
    Proc Natl Acad Sci U S A 100:15889-94. 2003
  7. pmc Ebola virus VP40-induced particle formation and association with the lipid bilayer
    L D Jasenosky
    Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin Madison, Madison, Wisconsin 53706, USA
    J Virol 75:5205-14. 2001
  8. pmc Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1
    St Patrick Reid
    Department of Microbiology, Box 1124, Mount Sinai School of Medicine, 1 Gustave L Levy Place, New York, NY 10029, USA
    J Virol 81:13469-77. 2007
  9. pmc Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture
    Gabriele Neumann
    Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin Madison, Madison, Wisconsin 53706, USA
    J Virol 76:406-10. 2002
  10. pmc Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function
    Victoria M Wahl-Jensen
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba
    J Virol 79:10442-50. 2005

Research Grants

  1. Analysis of the Ebola Virus VP24 Channel Protein
    RONALD HARTY; Fiscal Year: 2003
  2. EBOLA VIRUS INTERFERON-ANTAGONISTS AND VIRULENCE
    CHRISTOPHER BASLER; Fiscal Year: 2003
  3. Lassa and Nipah Virus Interferon-Antagonists
    CHRISTOPHER BASLER; Fiscal Year: 2003
  4. Ebola Virus VP40-Host Interactions In VIvo
    RONALD HARTY; Fiscal Year: 2005
  5. Budding of Negative-sense RNA Viruses
    RONALD HARTY; Fiscal Year: 2006
  6. Packaging of Ebola Virus RNA into Budding VLPs
    RONALD HARTY; Fiscal Year: 2008

Patents

  1. Vector comprising multiple homologous nucleotide sequences
  2. Vector comprising multiple homologous nucleotide sequences
  3. Vector comprising multiple homologous nucleotide sequences

Scientific Experts

  • Andreas Lucht
  • Takashi Kimura
  • Ziying Han
  • Mansour Mohamadzadeh
  • Reed F Johnson
  • Anthony Sanchez
  • RONALD HARTY
  • Sina Bavari
  • John C Kash
  • Kelly L Warfield
  • Alexander A Bukreyev
  • CHRISTOPHER BASLER
  • Ayato Takada
  • Heinz Feldmann
  • Yoshihiro Kawaoka
  • Amy L Hartman
  • Takeshi Noda
  • Sven Enterlein
  • St Patrick Reid
  • Gabriele Neumann
  • Viktor E Volchkov
  • Lawrence W Leung
  • Shinji Watanabe
  • E L Subbotina
  • Joanna Timmins
  • Hans Dieter Klenk
  • Elke Mühlberger
  • Jillian M Licata
  • Osvaldo Martinez
  • Nathalie Alazard-Dany
  • Valentina Volchkova
  • A A Chepurnov
  • Hideki Ebihara
  • Martina Trunschke
  • Stuart T Nichol
  • Steven Theriault
  • Rekha G Panchal
  • Lisa A Lopez
  • Huali Jin
  • Anthony C Wong
  • Mathieu Mateo
  • Daisy W Leung
  • Winfried Weissenhorn
  • Charalampos Valmas
  • Miguel J Martínez
  • Viktor Volchkov
  • Dipankar Das
  • Olivier Reynard
  • Sinu P John
  • Caroline Carbonnelle
  • Washington B Cardenas
  • Séverine Bär
  • Stephan Becker
  • Olga Dolnik
  • Steven Jones
  • Dana L Swenson
  • Darwyn Kobasa
  • Chris Druar
  • Jonathan S Towner
  • Nancy J Sullivan
  • Balaji Manicassamy
  • N V Tikunova
  • V E Volchkov
  • George Kallstrom
  • Victoria M Wahl-Jensen
  • H D Klenk
  • Hiroshi Sagara
  • M Javad Aman
  • Gordon Ruthel
  • Gary J Nabel
  • V A Volchkova
  • Rob W H Ruigrok
  • Guy Schoehn
  • F Xavier Gomis-Ruth
  • Yue Huang
  • Kristina Brauburger
  • Judith Olejnik
  • Dominik Conrad
  • M Saijo
  • L D Jasenosky
  • O Dolnik
  • CAROLINA B LOPEZ
  • Man Seong Park
  • Rohini G Sandesara
  • Bellur S Prabhakar
  • Zongdi Feng
  • Sean P Whelan
  • JoAnn M Tufariello
  • A Dessen
  • Richard B Honzatko

Detail Information

Publications63

  1. ncbi Ebola virus matrix protein VP40 interaction with human cellular factors Tsg101 and Nedd4
    Joanna Timmins
    European Molecular Biology Laboratory, 6 rue Jules Horowitz, 38042 Grenoble, France
    J Mol Biol 326:493-502. 2003
    ..These results suggest that hNedd4 and Tsg101 may play complimentary roles at a late stage of the assembly process, by recruiting cellular factors of two independent pathways to the site of budding at the plasma membrane...
  2. ncbi Ebola virus glycoprotein GP is not cytotoxic when expressed constitutively at a moderate level
    Nathalie Alazard-Dany
    Filovirus Laboratory, Claude Bernard University Lyon 1, INSERM U758, IFR 128 Biosciences Lyon Gerland, France
    J Gen Virol 87:1247-57. 2006
    ..These findings indicate that the synthesis of EBOV GP in virus-infected cells is controlled well by several mechanisms that do not allow GP overexpression and hence the early appearance of its cytotoxic properties...
  3. pmc Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles
    Jillian M Licata
    Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, 3800 Spruce St, Philadelphia, PA 19104 6049, USA
    J Virol 78:7344-51. 2004
    ..the C-terminal 50 amino acids of NP may be important for interacting with and enhancing release of VP40 VLPs. These findings provide a more complete understanding of the role of VP40 and additional Ebola virus proteins during budding...
  4. pmc Ebola virus can be effectively neutralized by antibody produced in natural human infection
    T Maruyama
    Departments of Immunology and Molecular Biology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 73:6024-30. 1999
    ..The neutralizing antibody may be useful in vaccine design and as a prophylactic agent against Ebola virus infection...
  5. pmc Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP
    Takeshi Noda
    Laboratory of Microbiology, Department of Disease Control, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo 060 0818, Japan
    J Virol 76:4855-65. 2002
    ..These results demonstrated the central role of VP40 in formation of the filamentous structure of Ebola virions and may suggest an interaction between VP40 and GP in morphogenesis...
  6. pmc Ebola virus-like particles protect from lethal Ebola virus infection
    Kelly L Warfield
    US Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA
    Proc Natl Acad Sci U S A 100:15889-94. 2003
    ..Together, our data suggest that eVLPs represent a promising vaccine candidate for protection against Ebola virus infections and a much needed tool to examine the genesis and nature of immune responses to Ebola virus...
  7. pmc Ebola virus VP40-induced particle formation and association with the lipid bilayer
    L D Jasenosky
    Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin Madison, Madison, Wisconsin 53706, USA
    J Virol 75:5205-14. 2001
    ..These data suggest that VP40 binds the lipid bilayer in an efficient yet structurally complex fashion...
  8. pmc Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1
    St Patrick Reid
    Department of Microbiology, Box 1124, Mount Sinai School of Medicine, 1 Gustave L Levy Place, New York, NY 10029, USA
    J Virol 81:13469-77. 2007
    ....
  9. pmc Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture
    Gabriele Neumann
    Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin Madison, Madison, Wisconsin 53706, USA
    J Virol 76:406-10. 2002
    ....
  10. pmc Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function
    Victoria M Wahl-Jensen
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba
    J Virol 79:10442-50. 2005
    ..Furthermore, sGP, the major soluble glycoprotein of Ebola virus, seems to possess an anti-inflammatory role by protecting the endothelial cell barrier function...
  11. pmc The Ebola virus VP35 protein functions as a type I IFN antagonist
    C F Basler
    Department of Microbiology, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    Proc Natl Acad Sci U S A 97:12289-94. 2000
    ..The Ebola virus VP35 therefore is likely to inhibit induction of type I IFN in Ebola virus-infected cells and may be an important determinant of Ebola virus virulence in vivo...
  12. pmc Molecular determinants of Ebola virus virulence in mice
    Hideki Ebihara
    Institute of Medical Science, University of Tokyo, Tokyo, Japan
    PLoS Pathog 2:e73. 2006
    ..These findings suggest a critical role for overcoming the interferon-induced antiviral state in the pathogenicity of EBOV and offer new insights into the pathogenesis of EBOV infection...
  13. ncbi Analysis of Ebola virus and VLP release using an immunocapture assay
    George Kallstrom
    Division of Virology, U S Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA
    J Virol Methods 127:1-9. 2005
    ..Furthermore, this assay can be used in surrogate models in non-biocontainment environment, facilitating both basic research on the mechanism of EBOV assembly and budding as well as drug-discovery research...
  14. ncbi Physicochemical properties of Marburg virus: evidence for three distinct virus strains and their relationship to Ebola virus
    M P Kiley
    Division of Viral Diseases, Centers for Disease Control, Atlanta, Georgia 30333
    J Gen Virol 69:1957-67. 1988
    ..In addition, these studies confirm the belief that MBG and EBO viruses are members of the new virus family, the Filoviridae...
  15. ncbi The assembly of Ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modification of nucleoprotein
    Yue Huang
    Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Mol Cell 10:307-16. 2002
    ..This distinct mechanism of regulation for filovirus assembly suggests new approaches for viral therapies and vaccines for Ebola and related viruses...
  16. pmc Ebolavirus VP35 suppresses IFN production from conventional but not plasmacytoid dendritic cells
    Lawrence W Leung
    Department of Microbiology, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    Immunol Cell Biol 89:792-802. 2011
    ..However, cells that utilize the TLR pathway can circumvent this inhibition, suggesting that the presence of multiple viral sensors enables the host to overcome viral immune evasion mechanisms...
  17. pmc Ebola virus glycoprotein toxicity is mediated by a dynamin-dependent protein-trafficking pathway
    Nancy J Sullivan
    Vaccine Research Center, National Institute for Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland 20814, USA
    J Virol 79:547-53. 2005
    ..By altering the trafficking of select cellular proteins, Ebola virus GP inflicts cell damage and may facilitate immune escape by the virus...
  18. pmc Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses
    Sina Bavari
    Dept of Cell Biology and Biochemistry, U S Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702 5011, USA
    J Exp Med 195:593-602. 2002
    ....
  19. pmc Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence
    John C Kash
    Department of Microbiology, School of Medicine, University of Washington, Box 358070, Seattle, Washington 98195 8070, USA
    J Virol 80:3009-20. 2006
    ..Taken together, these studies showed a correlation between antagonism of type I IFN responses and filovirus virulence...
  20. pmc Functional mapping of the nucleoprotein of Ebola virus
    Shinji Watanabe
    Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin Madison, 2015 Linden Dr, Madison, Wisconsin 53706, USA
    J Virol 80:3743-51. 2006
    ..These data advance our understanding of the functional region(s) of Ebola virus NP, which in turn should improve our knowledge of the Ebola virus life cycle and its extreme pathogenicity...
  21. pmc Ebolavirus VP24 binding to karyopherins is required for inhibition of interferon signaling
    Mathieu Mateo
    Laboratoire des Filovirus, INSERM U758, University Claude Bernard Lyon 1, 21 Av Tony Garnier, 69365 Lyon Cedex 07, France
    J Virol 84:1169-75. 2010
    ..We demonstrate that loss of function correlates with loss of binding to KPNalpha proteins. Thus, the VP24 IFN antagonist function requires the ability of VP24 to interact with KPNalpha...
  22. pmc In vivo oligomerization and raft localization of Ebola virus protein VP40 during vesicular budding
    Rekha G Panchal
    Developmental Therapeutics Program, Target Structure Based Drug Discovery Group, Science Applications International Corporation, National Cancer Institute, Frederick, MD 21702 1201, USA
    Proc Natl Acad Sci U S A 100:15936-41. 2003
    ..We also report the successful application of the biarsenic fluorophore, FlAsH, combined with a tetracysteine tag for imaging of Ebola VP40 in live cells...
  23. ncbi Classification, structure, and replication of filoviruses
    H Feldmann
    Institut fur Virologie, Philipps Universitat, Marburg, Germany
    Curr Top Microbiol Immunol 235:1-21. 1999
  24. pmc Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation
    St Patrick Reid
    Department of Microbiology, Box 1124, Mount Sinai School of Medicine, 1 Gustave L Levy Place, New York, NY 10029, USA
    J Virol 80:5156-67. 2006
    ..These data suggest that VP24 is likely to be an important virulence determinant that allows EBOV to evade the antiviral effects of IFNs...
  25. pmc The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3
    Christopher F Basler
    Department of Microbiology, Mount Sinai School of Medicine, 1 Gustave L Levy Place, New York, NY 10029, USA
    J Virol 77:7945-56. 2003
    ..These data suggest that in Ebola virus-infected cells, VP35 inhibits the induction of antiviral genes, including the IFN-beta gene, by blocking IRF-3 activation...
  26. pmc Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling
    Washington B Cardenas
    Department of Microbiology, Mount Sinai School of Medicine, 1 Gustave L Levy Place, New York, NY 10029, USA
    J Virol 80:5168-78. 2006
    ..These data support the hypothesis that dsRNA binding may contribute to VP35 IFN antagonist function. However, additional mechanisms of inhibition, at a point proximal to the IRF-3 kinases, most likely also exist...
  27. pmc Reverse genetic generation of recombinant Zaire Ebola viruses containing disrupted IRF-3 inhibitory domains results in attenuated virus growth in vitro and higher levels of IRF-3 activation without inhibiting viral transcription or replication
    Amy L Hartman
    Special Pathogens Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, MS G 14, Atlanta, GA 30329, USA
    J Virol 80:6430-40. 2006
    ....
  28. pmc Crystal structure of the matrix protein VP40 from Ebola virus
    A Dessen
    European Molecular Biology Laboratory Grenoble Outstation, 6 rue Jules Horowitz, 38000 Grenoble, France
    EMBO J 19:4228-36. 2000
    ..The crystal structure reveals how the molecule may be able to switch from a monomeric conformation to a hexameric form, as observed in vitro. Its implications for the assembly process are discussed...
  29. pmc Biochemical and functional characterization of the Ebola virus VP24 protein: implications for a role in virus assembly and budding
    Ziying Han
    Laboratory 412 Laboratory 413, Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104 6049, USA
    J Virol 77:1793-800. 2003
    ..These data indicate that VP24 possesses structural features commonly associated with viral matrix proteins and that VP24 may have a role in virus assembly and budding...
  30. ncbi Downregulation of beta1 integrins by Ebola virus glycoprotein: implication for virus entry
    A Takada
    Laboratory of Microbiology, Graduate School of Veterinary Medicine, Sapporo, 060 0818, Japan
    Virology 278:20-6. 2000
    ..We suggest that integrins, especially the beta1 group, might interact with the GP and perhaps be involved in Ebola virus entry into cells...
  31. ncbi Biosynthesis and role of filoviral glycoproteins
    H Feldmann
    Canadian Science Centre for Human and Animal Health, 1015 Arlington Street, Winnipeg, Manitoba, Canada R3E 3R2
    J Gen Virol 82:2839-48. 2001
  32. pmc Overlapping motifs (PTAP and PPEY) within the Ebola virus VP40 protein function independently as late budding domains: involvement of host proteins TSG101 and VPS-4
    Jillian M Licata
    Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104 6049, USA
    J Virol 77:1812-9. 2003
    ..These results provide important insights into the complex interplay between viral and host proteins during the late stages of Ebola virus budding...
  33. pmc Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35
    Daisy W Leung
    Department of Biochemistry, Biophysics and Molecular Biology, Iowa State University, Ames, Iowa, USA
    Nat Struct Mol Biol 17:165-72. 2010
    ..These results suggest that simultaneous recognition of dsRNA backbone and blunt ends provides a mechanism by which Ebola VP35 antagonizes host dsRNA sensors and immune responses...
  34. pmc Mapping of the VP40-binding regions of the nucleoprotein of Ebola virus
    Takeshi Noda
    Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin Madison, 2015 Linden Drive, Madison, WI 53706, USA
    J Virol 81:3554-62. 2007
    ..These findings enhance our understanding of Ebola virus assembly and in so doing move us closer to the identification of targets for the development of antiviral compounds to combat Ebola virus infection...
  35. pmc Ebola virus VP40 late domains are not essential for viral replication in cell culture
    Gabriele Neumann
    Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin Madison, 2015 Linden Dr, Madison, WI 53706, USA
    J Virol 79:10300-7. 2005
    ..These findings indicate that the Ebola VP40 late domain motifs enhance virus replication but are not absolutely required for virus replication in cell culture...
  36. pmc VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice
    Sven Enterlein
    Department of Virology, Philipps University Marburg, Hans Meerwein str 3, 35043 Marburg, Germany
    Antimicrob Agents Chemother 50:984-93. 2006
    ..Together, these data suggest that antisense PMO and P-PMO have the potential to control EBOV infection and are promising therapeutic candidates...
  37. pmc The L-VP35 and L-L interaction domains reside in the amino terminus of the Ebola virus L protein and are potential targets for antivirals
    Martina Trunschke
    Department of Virology, Philipps University of Marburg, Hans Meerwein Strβe 2, 35043 Marburg, Germany
    Virology 441:135-45. 2013
    ....
  38. pmc Enzyme-linked immunosorbent assays for detection of antibodies to Ebola and Marburg viruses using recombinant nucleoproteins
    M Saijo
    Special Pathogens Laboratory, Department of Virology 1, National Institute of Infectious Diseases, Gakuen 4 7 1, Musashimurayama, Tokyo 208 0011, Japan
    J Clin Microbiol 39:1-7. 2001
    ..The results indicate that ELISA systems prepared with the recombinant NPs of EBO and MBG are valuable tools for the diagnosis of EBO and MBG infections and for seroepidemiological field studies...
  39. pmc A system for functional analysis of Ebola virus glycoprotein
    A Takada
    Department of Virology and Molecular Biology, St Jude Children s Research Hospital, 332 North Lauderdale, P O Box 318, Memphis, TN 38101, USA
    Proc Natl Acad Sci U S A 94:14764-9. 1997
    ..Thus, our VSV system should be useful for investigating the functions of glycoproteins from highly pathogenic viruses or those incapable of being cultured in vitro...
  40. ncbi Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins
    Z Yang
    Howard Hughes Medical Institute and Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA
    Science 279:1034-7. 1998
    ....
  41. pmc Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal
    Lisa A Lopez
    Department of Molecular Microbiology and Immunology, USC Keck School of Medicine, 2011 Zonal Ave, HMR502, Los Angeles, CA 90033, USA
    J Virol 84:7243-55. 2010
    ..Moreover, GP overcame restriction without significantly removing tetherin from the cell surface. These findings suggest that Ebola virus GP uses a novel mechanism to circumvent tetherin restriction...
  42. pmc Biochemical analysis of the secreted and virion glycoproteins of Ebola virus
    A Sanchez
    Special Pathogens Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    J Virol 72:6442-7. 1998
    ..We also determined that SGP is secreted from infected cells almost exclusively in the form of a homodimer that is joined by disulfide bonding...
  43. ncbi The nonstructural small glycoprotein sGP of Ebola virus is secreted as an antiparallel-orientated homodimer
    V A Volchkova
    Institut fur Virologie, Philipps Universitat, Robert Koch Strasse 17, Marburg, D 35037, Germany
    Virology 250:408-14. 1998
    ....
  44. pmc A forward genetic strategy reveals destabilizing mutations in the Ebolavirus glycoprotein that alter its protease dependence during cell entry
    Anthony C Wong
    Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    J Virol 84:163-75. 2010
    ..Altogether, our findings suggest that CatB cleavage is required to facilitate the triggering of viral membrane fusion by destabilizing the prefusion conformation of EBOV GP...
  45. pmc The VP35 protein of Ebola virus impairs dendritic cell maturation induced by virus and lipopolysaccharide
    Huali Jin
    Department of Microbiology and Immunology, College of Medicine, University of Illinois, Chicago, IL 60612, USA
    J Gen Virol 91:352-61. 2010
    ..Our work highlights a critical role of VP35 in viral interference in DC function with resultant deficiency in T-cell function, which may contribute to the profound virulence of Ebola virus infection...
  46. pmc Role of Ebola virus VP30 in transcription reinitiation
    Miguel J Martínez
    INSERM, U758, Filovirus Laboratory, 21 Av Tony Garnier, 69365 Lyon, Cedex 07, France
    J Virol 82:12569-73. 2008
    ..We demonstrate that VP30 is involved in reinitiation of gene transcription and that this activity is affected by mutations at the phosphorylation sites...
  47. ncbi Ebola virus inhibits induction of genes by double-stranded RNA in endothelial cells
    B H Harcourt
    Winship Cancer Center, Emory University, Atlanta, Georgia 30322, USA
    Virology 252:179-88. 1998
    ..Inhibition of IFN and dsRNA responsiveness could play a role in the immunosuppression seen in EZ infections and would play a role in the pathogenesis of disease caused by EZ...
  48. pmc Ebola virus VP30 is an RNA binding protein
    Sinu P John
    Graduate Program in Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
    J Virol 81:8967-76. 2007
    ..Thus, we show for the first time the direct interaction of EBOV VP30 with RNA and the importance of the N-terminal region for binding RNA...
  49. ncbi Differential expression of the Ebola virus GP(1,2) protein and its fragments in E. coli
    Dipankar Das
    University of Alberta, Edmonton, Alta, Canada T6G 2N8
    Protein Expr Purif 54:117-25. 2007
    ....
  50. ncbi [Molecular mechanisms of Ebola virus reproduction]
    E L Subbotina
    Vopr Virusol 52:10-6. 2007
    ....
  51. ncbi Analysis of the expressed heavy chain variable-region genes of Macaca fascicularis and isolation of monoclonal antibodies specific for the Ebola virus' soluble glycoprotein
    Chris Druar
    Cangene Corporation, 3404 American Drive, Mississauga, Ontario L4V 1T4, Canada
    Immunogenetics 57:730-8. 2005
    ..In summary, the study provides new insight into the M. fascicularis V region gene repertoire and further supports the idea that macaque-derived mAbs may be of therapeutic value to humans...
  52. ncbi [The properties of Ebola virus proteins]
    E L Subbotina
    Vopr Virusol 51:4-10. 2006
    ....
  53. ncbi Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity
    V E Volchkov
    Institut fur Virologie, Philipps Universitat, Robert Koch Strasse 17, 35037 Marburg, Germany
    Science 291:1965-9. 2001
    ..The mutant was significantly more cytotoxic than wild-type virus, indicating that cytotoxicity caused by GP is down-regulated by the virus through transcriptional RNA editing and expression of sGP...
  54. ncbi The matrix protein VP40 from Ebola virus octamerizes into pore-like structures with specific RNA binding properties
    F Xavier Gomis-Ruth
    European Molecular Biology Laboratory EMBL, 6 rue Jules Horowitz, 38042, Grenoble, France
    Structure 11:423-33. 2003
    ..SDS-resistant octameric VP40 is also found in Ebola virus-infected cells, which suggests that VP40 has an additional function in the life cycle of the virus besides promoting virus assembly and budding off the plasma membrane...
  55. pmc Antibody-dependent enhancement of Ebola virus infection
    Ayato Takada
    Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo 108 8639, Japan
    J Virol 77:7539-44. 2003
    ..Our results suggest a novel mechanism of antibody-dependent enhancement of Ebola virus infection, one that would account for the dire outcome of Ebola outbreaks in human populations...
  56. ncbi Oligomerization and polymerization of the filovirus matrix protein VP40
    Joanna Timmins
    European Molecular Biology Laboratory, 6 rue Jules Horowitz, 38042 Grenoble, France
    Virology 312:359-68. 2003
    ..Interestingly, Marburg virus VP40 rings reveal a high tendency to polymerize into rods composed of stacked rings. These results may suggest distinct roles for different oligomeric forms of VP40 in the filovirus life cycle...
  57. ncbi A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus
    Amy L Hartman
    Special Pathogens Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road MS G 14 Atlanta, GA 30329, USA
    Virology 328:177-84. 2004
    ..Remarkably, this basic amino acid motif displayed high sequence identity with part of the N-terminal RNA-binding domain of another interferon-antagonist, the NS1 protein of influenza A virus...
  58. ncbi Rescue of Ebola virus from cDNA using heterologous support proteins
    Steven Theriault
    Special Pathogens Program, National Laboratory for Zoonotic Diseases and Special Pathogens, National Microbiology Laboratory, Health Canada, Canada
    Virus Res 106:43-50. 2004
    ..In contrast to previous data, viral proteins were able to target heterologous filovirus RNA. Together these results indicated that protein-protein interactions are more critical than protein-RNA interactions...
  59. pmc Comprehensive analysis of ebola virus GP1 in viral entry
    Balaji Manicassamy
    Department of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, E829 MSB, 835 S Wolcott Ave, Chicago, IL 60612, USA
    J Virol 79:4793-805. 2005
    ..These results provide information for elucidating the structural and functional roles of the filoviral glycoproteins and for developing potential therapeutics to block viral entry...
  60. pmc Detection of cell-cell fusion mediated by Ebola virus glycoproteins
    Séverine Bär
    Department of Cell Biology, Institut Cochin, INSERM U567, CNRS UMR 8104, Universite Rene Descartes, Paris, France
    J Virol 80:2815-22. 2006
    ..This unexpected feature, possibly related to the nature of the EboV receptor, could explain the impossibility of inducing formation of syncytia among GP-expressing cells...
  61. ncbi Polymorphism of filovirus glycoproteins
    Viktor E Volchkov
    Biologie des Filovirus, Claude Bernard University Lyon, INSERM U412 69365 Lyon, France
    Adv Virus Res 64:359-81. 2005
  62. pmc Rescue of recombinant Marburg virus from cDNA is dependent on nucleocapsid protein VP30
    Sven Enterlein
    Department of Virology, Philipps University Marburg, Robert Koch str 17, 35037 Marburg, Germany
    J Virol 80:1038-43. 2006
    ..In contrast, rescue of recombinant EBOV was not supported by EBOV VP30 containing a mutated Zn-binding domain...
  63. ncbi [Human recombinant antibodies to Ebola virus: preparation and characteristics]
    N V Tikunova
    Vopr Virusol 50:25-9. 2005
    ..One of the selected antibodies reacted with two EP proteins: VP24 and VP40. Solid-phase EIA demonstrated cross-reactivity with Marburg virus (MAR) and defined VP24 MAR as a target protein for the antibody...

Research Grants6

  1. Analysis of the Ebola Virus VP24 Channel Protein
    RONALD HARTY; Fiscal Year: 2003
    ..Overall this application will address key mechanisms of Ebola virus pathogenesis that may lead to the development of novel paradigms with direct impact on the development of therapeutic approaches. ..
  2. EBOLA VIRUS INTERFERON-ANTAGONISTS AND VIRULENCE
    CHRISTOPHER BASLER; Fiscal Year: 2003
    ..VP35 and VP24 may also prove to be attractive targets for new antiviral agents. Inhibition of anti-IFN factors may sensitize Ebola virus infected cells to the antiviral effects of IFN and may also enhance the effect of antiviral agents. ..
  3. Lassa and Nipah Virus Interferon-Antagonists
    CHRISTOPHER BASLER; Fiscal Year: 2003
    ..abstract_text> ..
  4. Ebola Virus VP40-Host Interactions In VIvo
    RONALD HARTY; Fiscal Year: 2005
    ..These studies will be fundamental for our understanding of Ebola virus budding and necessary for the successful development of future therapeutic approaches. ..
  5. Budding of Negative-sense RNA Viruses
    RONALD HARTY; Fiscal Year: 2006
    ....
  6. Packaging of Ebola Virus RNA into Budding VLPs
    RONALD HARTY; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..

Patents3

  1. Vector comprising multiple homologous nucleotide sequences
    Patent Number: JP2015128443-A; Date:2015-07-16
  2. Vector comprising multiple homologous nucleotide sequences
    Patent Number: WO2010057650-A1; Date:2010-05-27
  3. Vector comprising multiple homologous nucleotide sequences
    Patent Number: JP2012509073-A; Date:2012-04-19